Clinically used iron chelator deferasirox (6) was shown to potently inhibit KDM4A in vitro, and some of its derivatives with improved cell permeability were shown to significantly upregulate histone trimethylation and act as potent cancer cell growth inhibitors. The gene discussed is KDM4A; the disease is cancer.